Labcorp Holdings Inc. has announced the continued expansion of its molecular residual disease (MRD) portfolio, aimed at enabling earlier detection of cancer recurrence compared to traditional imaging methods. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I-III breast cancer or stage I-IIIA non-small cell lung cancer, as well as the nationwide availability of Labcorp Plasma Detect Genome, a whole-genome MRD test for stage III colon cancer. Labcorp has several ongoing and completed clinical studies that demonstrate the clinical utility of Labcorp Plasma Detect for tracking early disease progression, predicting long-term outcomes, and identifying residual cancer. Recent peer-reviewed publications have highlighted studies focusing on diffuse pleural mesothelioma and head and neck cancer. Additionally, data outlining the continued development of Labcorp Plasma Detect Genome MRD were presented at the recent AMP 2025 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC61831) on January 13, 2026, and is solely responsible for the information contained therein.